Where does Organon's cash flow data come from?

Every line is extracted from Organon's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Organon OGN Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Net income	——	$864M-15.5%	$1.02B+11.6%	$917M-32.1%
Depreciation and amortization	$156M+18.2%	$132M+10.0%	$120M+25.0%	$96M+4.3%
Stock-based compensation	$77M-26.7%	$105M+4.0%	$101M+34.7%	$75M+27.1%
Deferred income taxes	$63M+137%	-$170M+64.9%	-$485M-2,594%	-$18M+93.8%
Gain (loss) on sale of assets	——	——	——	——
Change in accounts receivable	-$79M—	——	$218M+69.0%	$129M—
Change in inventories	——	$131M-43.0%	$230M+4.5%	$220M+59.4%
Change in accounts payable	——	——	$163M—	——
Change in accrued liabilities	-$142M—	——	$102M-40.7%	$172M—
Other working capital changes	-$139M—	——	——	$8M+115%
Change in income taxes payable/receivable	-$61M+6.2%	-$65M-506%	$16M—	——
Change in other current assets	——	$236M—	——	——
Change in fair value of contingent consideration	$50M+555%	-$11M—	$0—	$0—
Net cash from operating activities	$700M-25.5%	$939M+17.5%	$799M-6.9%	$858M-60.3%
Capital expenditures	$162M-7.4%	$175M-30.3%	$251M+28.1%	$196M+2.1%
Acquisitions, net of cash acquired	——	$166M—	$0—	$0—
Proceeds from sale of businesses	——	——	——	——
Purchases of intangible assets	——	$105M+5,150%	$2M-98.4%	$124M—
Acquired in-process research and development	——	$71M—	——	$109M+4.8%
Net cash from investing activities	-$390M+24.0%	-$513M-97.3%	-$260M+38.1%	-$420M+12.7%
Dividends paid	$88M-70.4%	$297M+1.0%	$294M+1.4%	$290M+100%
Proceeds from issuance of debt	$1.06B-11.0%	$1.19B+1,383%	$80M—	——
Repayments of debt	$1.51B+26.4%	$1.2B+254%	$338M+213%	$108M-1.8%
Taxes paid for net share settlement	$15M-31.8%	$22M+29.4%	$17M+54.5%	$11M—
Net cash from financing activities	-$561M-52.4%	-$368M+35.3%	-$569M-31.4%	-$433M—
Effect of exchange rate changes on cash	$150M+297%	-$76M—	——	——
Net increase (decrease) in cash	——	-$18M—	——	——
Amortization	$205M+41.4%	$145M+25.0%	$116M0.0%	$116M+12.6%
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset	$50M+555%	-$11M—	$0—	——
Depreciation	$156M+18.2%	$132M+10.0%	$120M+25.0%	$96M+4.3%
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax	$21M—	——	-$40M—	——
Gain on sale of business and assets	——	——	——	——
Accounts payable	——	——	$163M—	——
Increase (Decrease) in Other Current Assets	——	$236M—	——	——
Impairment of assets and other charges	$9M—	$0—	$0—	——
Other Noncash Income (Expense)	-$87M-112%	-$41M-32.3%	-$31M-19.2%	-$26M-117%
Acquired in-process research and development and milestones	$6M-92.6%	$81M+913%	$8M—	——
Other Payments to Acquire Businesses	——	$166M—	$0—	$0—
Payments to Acquire in Process Research and Development	——	$71M—	——	$107M—
Payments to Acquire Intangible Assets	——	$105M+5,150%	$2M-98.4%	$124M—
Free cash flow	$538M-29.6%	$764M+29.1%	$592M-10.6%	$662M-66.6%
Free cash flow	$538M-29.6%	$764M+29.1%	$592M-10.6%	$662M-66.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Organon's cash flow data come from?: Every line is extracted from Organon's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.